Nanogen Company Description
Nanogen digs into DNA to diagnose disease. The company makes diagnostic reagents, instruments, and test kits that detect a variety of infectious diseases -- including several herpes viruses and influenza -- as well as some cancers and genetic conditions. Its Q-PCR Alert and MGB Alert tests employ real-time PCR technology (a method of DNA amplification commonly used in molecular testing) and its proprietary MGB technology. Nanogen also makes point-of-care tests, including a couple of tests administered in the emergency room to diagnose heart attack and congestive heart failure. Nanogen filed for Chapter 11 bankruptcy protection in 2009; it then sold all of its assets to French diagnostics company Elitech for about $26 million.
View the Comprehensive Company Description for Nanogen
The Company Description provides a historical perspective of Nanogen's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Nanogen's evolution in the marketplace.
